Antithrombotic Treatment for Chronic Coronary Syndrome: Evidence and Future Perspectives
Research output: Contribution to journal › Review › Research › peer-review
Standard
Antithrombotic Treatment for Chronic Coronary Syndrome : Evidence and Future Perspectives. / Kulasingam, Archana; Pareek, Manan; Gragnano, Felice; Würtz, Morten; Pryds, Kasper; Calabrò, Paolo; Grove, Erik Lerkevang.
In: Cardiology (Switzerland), 2024, p. 1-11.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Antithrombotic Treatment for Chronic Coronary Syndrome
T2 - Evidence and Future Perspectives
AU - Kulasingam, Archana
AU - Pareek, Manan
AU - Gragnano, Felice
AU - Würtz, Morten
AU - Pryds, Kasper
AU - Calabrò, Paolo
AU - Grove, Erik Lerkevang
N1 - Publisher Copyright: © 2024 S. Karger AG, Basel.
PY - 2024
Y1 - 2024
N2 - Background: The clinical presentation of coronary artery disease can range from asymptomatic, through stable disease in the form of chronic coronary syndrome, to acute coronary syndrome. Chronic coronary syndrome is a frequent condition, and secondary prevention of ischaemic events is essential. Summary: Antithrombotic therapy is a key component of secondary prevention strategies, and it may vary in type and intensity depending on patient characteristics, comorbidities, and revascularisation modalities. Dual antiplatelet therapy is the default strategy in patients with chronic coronary syndrome and recent coronary stent implantation, while antiplatelet monotherapy is commonly prescribed for long-term prevention of cardiovascular events. Oral anticoagulation, in combination with antiplatelet therapy or alone, is used in patients with, e.g., concomitant atrial fibrillation or venous thromboembolism. Key Messages: This review provides an overview of antithrombotic treatment strategies in patients with chronic coronary syndrome. Key messages from current guidelines are conveyed, and we provide future perspectives on long-term antithrombotic strategies.
AB - Background: The clinical presentation of coronary artery disease can range from asymptomatic, through stable disease in the form of chronic coronary syndrome, to acute coronary syndrome. Chronic coronary syndrome is a frequent condition, and secondary prevention of ischaemic events is essential. Summary: Antithrombotic therapy is a key component of secondary prevention strategies, and it may vary in type and intensity depending on patient characteristics, comorbidities, and revascularisation modalities. Dual antiplatelet therapy is the default strategy in patients with chronic coronary syndrome and recent coronary stent implantation, while antiplatelet monotherapy is commonly prescribed for long-term prevention of cardiovascular events. Oral anticoagulation, in combination with antiplatelet therapy or alone, is used in patients with, e.g., concomitant atrial fibrillation or venous thromboembolism. Key Messages: This review provides an overview of antithrombotic treatment strategies in patients with chronic coronary syndrome. Key messages from current guidelines are conveyed, and we provide future perspectives on long-term antithrombotic strategies.
KW - Antiplatelet agents
KW - Antithrombotic drugs
KW - Chronic coronary syndrome
KW - Coronary artery disease
UR - http://www.scopus.com/inward/record.url?scp=85194498213&partnerID=8YFLogxK
U2 - 10.1159/000537706
DO - 10.1159/000537706
M3 - Review
C2 - 38354713
AN - SCOPUS:85194498213
SP - 1
EP - 11
JO - Cardiologia
JF - Cardiologia
SN - 0008-6312
ER -
ID: 394709190